HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clearasil sales

This article was originally published in The Rose Sheet

Executive Summary

"Good progress" has been made on the integration and rejuvenation of the acne treatment brand, which contributed over $114.5 mil. (£1=$1.46) in sales worldwide in its first full year, Boots says in its fiscal 2002 financial review May 30. Operating profits for the brand rose by over 13% to $97.9 mil. for the year ended March 31 and the total investment in Clearasil reached $165.8 mil., retailer adds. In the U.S., retail sales for Clearasil were up 1% to $34.4 mil. in the 52 weeks ended April 21, according to Information Resources, Inc. data for food, drug and mass outlets, excluding Wal-Mart...

You may also be interested in...

NeuClone’s Trastuzumab Trial Succeeds

NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.

EMA Prepares Approval Verdict On Beovu, Idhifa, Recarbrio

Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.

New Zealand Reverse-Switches Codeine Judging Risks Outweigh Benefits

New Zealand is the latest country to reverse-switch all codeine-containing OTC drugs to prescription-only status following a protracted consultation process, during which industry's protestations fell on deaf ears.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts